Skip to main content

Search

Search the site:

News, Views, and Advocacy From the Oncology Nursing Society

News & Views

Advocacy

Stories

News & Views

Latest Articles
Clinical Practice
ONS News
ONS Leadership

Trending Topics

Treatments
Research
COVID-19
Safety
Drug Reference Sheet
Clinical practice

View All Topics

Advocacy

Latest Articles
Updates
Get Involved

Stories View All

View All

When the Provider Becomes the Patient: What I Learned From COVID-19

When the Provider Becomes the Patient: What I Learned From COVID-19

The Case of the Late Head and Neck Lymphedema

Clinical practice

The Case of the Late Head and Neck Lymphedema

Our Patients Give Us Peace in Unexpected Circumstances

Oncology nurse pride

Our Patients Give Us Peace in Unexpected Circumstances

Behind Our Masks, I See You, I Hear You

Behind Our Masks, I See You, I Hear You

Connect With Your Patients on a Human Level as Well as a Healthcare Level

Oncology nurse-patient relationship

Connect With Your Patients on a Human Level as Well as a Healthcare Level

Search

News & Views

Advocacy

Stories

Home

Author Content

Drug Reference Sheet

Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl

Based on LOTIS-2 trial results that reported an overall response rate of nearly 50%, in April 2021 the U.S. Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta^TM) for adults with relapsed or refractory large B-cell lymphoma.

Patient resources

What Patients and Oncology Nurses Need to Know About Vaccination and Cancer

People with cancer have a particular risk for infection, and vaccines can be a powerful preventive tool. According to the World Health Organization, immunization prevents 2–3 million deaths every year worldwide from diseases, including diphtheria, influenza, and measles. Here’s what patients and nurses need to know about vaccines and guidelines for people with cancer.

Drug Reference Sheet

Oncology Drug Reference Sheet: Ivosidenib

Adding to its earlier approvals for use in adults with acute myeloid leukemia (AML), on August 25, 2021, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo^®) for adults with previously treated, locally advanced or metastatic cholangiocarcinoma. Cholangiocarcinoma, or cancer of the bile ducts, is a rare cancer, and ivosidenib is the only currently approved agent for patients with an IDH1 variant.

January 25, 2022

Drug Reference Sheet

Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf

A first-of-its-kind antibody-drug conjugate for multiple myeloma, belantamab mafodotin-blmf (Blenrep) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2020. The approval was based on clinical trial findings that demonstrated a 31% overall response rate that lasted at least six months in 73% of responders.

October 26, 2021

Clinical practice

What Is a Liquid Biopsy?

All cells (healthy cells and tumor cells) in the body shed DNA, called cell-free DNA (cfDNA). When it’s only from tumor cells, it’s referred to as circulating tumor DNA (ctDNA), although cfDNA and ctDNA are sometimes used interchangeably.

October 25, 2021

Clinical practice

Oncology Drug Reference Sheet: Relugolix

On December 18, 2020, the U.S. Food and Drug Administration approved relugolix (Orgovyx^TM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer.

Be Alert for Axillary Adenopathy After COVID-19 Vaccination

Nearly 60 million people in the United States and almost 200 million around the world have received the COVID-19 coronavirus vaccine as of mid-February 2021, and the numbers will continue to grow as more doses come to market and other manufacturers’ versions receive emergency use authorizations. As more people get vaccinated, some of the expected side effects are being observed in clinical practice and have implications for cancer care.

February 19, 2021

Oncology drug research

Oncology Drug Reference Sheet: Tafasitamab-Cxix

Tafasitamab-cxix (Monjuvi^®) received accelerated approval from the U.S. Food and Drug Administration in July 2020 in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma.

January 26, 2021

COVID-19 Reference Sheet: Vaccines

To control the COVID-19 coronavirus pandemic, society needs public health measures (e.g., masks, physical distancing, hand washing), treatments for infection, and vaccines to prevent infection or serious disease. As the most trusted profession, nurses have a responsibility to educate patients and the community about the facts and science behind the vaccines. This reference sheet will help guide those conversations and is regularly updated as new information is released.

December 14, 2020

Clinical practice

Oncology Drug Reference Sheet: Lurbinectedin

In June 2020, the U.S. Food and Drug Administration granted accelerated approval to lurbinectedin (Zepzelca^TM) for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The approval adds a second choice for patients who experience treatment-resistant SCLC progression, who previously had only topotecan as an option.

October 20, 2020

U.S. Food and Drug Administration (FDA)

Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv

Enfortumab vedotin-ejfv (Padcev™) was granted accelerated approval in December 2019 for adults with locally advanced or metastatic urothelial cancer who previously received an immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) and platinum-containing therapy.

A Perspective on COVID-19 for New and Student Nurses

COVID-19 coronavirus’s ripple effects extend so far beyond health and health care. Life in the United States doesn’t look the same as it did a few months ago. We’re all affected in some way, but senior nursing students have a distinct set of circumstances related to the pandemic.

Oncology Drug Reference Sheet: Tocilizumab

Tocilizumab was approved in August 2017 for the treatment of chimeric antigen receptor T cell–induced cytokine release syndrome. In March 2020, the U.S. Food and Drug Administration approved a randomized, double-blind, placebo-controlled, phase III clinical trial to assess the safety and efficacy of tocilizumab plus standard of care in patients hospitalized with severe COVID-19 pneumonia.

Clinical practice

Emotional Coping Strategies for COVID-19

The COVID-19 novel coronavirus pandemic is turning the world, inside and outside of the hospital, upside down. Not only are oncology nurses seeing high demands at work, but changes and restrictions are being instated at home as well.

Clinical practice

COVID-19 Fact Sheet and Implications for Patients With Cancer

COVID-19 is a novel coronavirus (a large family of viruses that can cause cold-like illnesses) first identified in December 2019. It is a respiratory illness and can be spread from person to person through respiratory droplets during close contact. The first case of COVID-19 in the United States was reported on January 21, 2020.

Oncology Drug Reference Sheet: Niraparib

Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer.

February 25, 2020

Oncology Drug Reference Sheet: Radium 223 Dichloride

Radium 223 dichloride (Xofigo^®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

December 24, 2019

Oncology nurse scientist

Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips

The future of cancer care is here: precision medicine has led to many of today’s newest cancer treatments and has made incredible progress since former President Barak Obama first announced the U.S. Precision Medicine Initiative (PMI) in 2015.

Oncology Drug Reference Sheet: Combination Trastuzumab and Hyaluronidase-Oysk

A new product that combines trastuzumab and hyaluronidase (Herceptin Hylecta™) received U.S. Food and Drug Administration approval in February 2019 for the treatment of HER2-overexpressing breast cancer. The approval was based on the results of two randomized trials: HannaH and SafeHER.

Which Ambulatory Infusion Pump Is Best for 5-FU?

Because of its long infusion time over 46–48 hours, 5-fluorouracil (5-FU) is usually administered with an ambulatory infusion pump in the outpatient setting. However, two types of pumps exist. On one side of the spectrum is the elastomeric pump: small, compact, but gets the job done. On the other is the electronic pump: bigger, flashy, with lots of bells and whistles (literally). Here are the advantages and disadvantages of each.

Study Finds Three Priority Steps to Improve Cancer Survivorship

Healthcare providers need to address three priority areas to improve outcomes for cancer survivors and support caregivers for patients with cancer, according to findings from an evidence review published in CA: A Cancer Journal for Clinicians.

January 23, 2019

Oncology Drug Reference Sheet: Lutetium Lu 177 Dotatate

Lutetium Lu 177 dototate (Lutathera^®) was approved in January 2018 by the U.S. Food and Drug Administration to treat a specific group of neuroendocrine tumors (NETs) in the gastrointestinal tract. NETs are rare, and the tumors produce hormone-like substances in response to signals from the nervous system.

January 23, 2019

Advanced Practice Nursing (APRN)

What APRNs Need to Know About Right to Try

The Right-to-Try law, which has been in effect since May 2018, may have a misleading name, given that it doesn’t require drug manufacturers to grant access to experimental treatments that have passed phase I trials to any patient who seeks it. Rather, the law grants terminally ill patients the “right to ask” the drug company directly, but the request can be denied for several reasons (e.g., limited supply, expense).

October 16, 2018

Clinical practice guidelines

TNM Gets an Upgrade in Eighth Edition Staging Guidelines

Nearly a century ago, cancer staging was a simple categorization of disease as either local, regional, or distant. Then in the 1940s, a French surgeon developed the concept for a staging system that uses the size of the primary tumor (T), its lymphatic involvement (N), and the presence of metastases (M) to stage a patient’s cancer based on the anatomic extent of the disease at the time of diagnosis.

August 09, 2018

To discuss the information in this article with other oncology nurses, visit the ONS Communities.

To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®

News, Views, and Advocacy From the Oncology Nursing Society

Legal Notices

Contact Us

Conferences

Advertising

Newsroom

Sitemap

Oncology Nursing Foundation

© Copyright 2022 Oncology Nursing Society

Back to Top ▲